DEFEROXAMINE (DESFERRIOXAMINE) - NEW TOXICITIES FOR AN OLD DRUG

被引：45

作者：

BENTUR, Y

MCGUIGAN, M

KOREN, G

机构：

[1] Israel Poison Information Center, Rambam Medical Center, Faculty of Medicine, Technion, Haifa

[2] Division of Clinical Pharmacology and Toxicology, Poison Information Center, The Hospital for Sick Children, Toronto, Ontario

来源：

DRUG SAFETY | 1991年 / 6卷 / 01期

关键词：

D O I：

10.2165/00002018-199106010-00004

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Iron is an essential element for body homoeostasis, but there is no effective mechanism for elimination of an excess of this mineral. Deferoxamine (desferrioxamine) is currently the treatment of choice for iron overload states from both acute iron intoxication and transfusion-dependent anaemias. The pharmacokinetics of deferoxamine are confounded both by its ability to chelate endogenous and exogenous iron and by the laboratory techniques used for its determination. Its iron-complex (ferrioxamine) has different pharmacokinetic properties. Because of its effectiveness, the use of deferoxamine is becoming more common, involving long term and high dose regimens. As a result of this, more and more toxicities that were not known in the past have been described and characterised. The most serious of these include hypotension, renal insufficiency, neurotoxicity, growth retardation and opportunistic infections; some of these side effects may be attributed to or aggravated by ferrioxamine. The pharmacological and toxicological literature on deferoxamine, and possible mechanisms for its toxicity, are reviewed and discussed.

引用

页码：37 / 46

页数：10

共 89 条

[51] Monteagudo F.S.E., Cassidy M.J.D., Folb P.I., Recent developments in aluminium toxicology, Medical Toxicology, 4, pp. 1-6, (1989)
[52] Olivieri N.F., Buncic J.R., Chew E., Et al., Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions, New England Journal of Medicine, 314, pp. 869-873, (1986)
[53] Pall H., Bloke D.R., Winyard P., Lunec J., Willia A., Et al., Ocular toxicity of desferrioxamine —an example of copper promoted auto-oxidative damage?, British Journal of Ophthalmology, 73, pp. 42-47, (1989)
[54] Peters G., Keberle H., Schmid K., Brunner H., Distribution and renal excretion of desferrioxamine and ferrioxamine in the dog and the rat, Biochemical Pharmacology, 15, pp. 93-109, (1966)
[55] Pippard M.J., Iron chelation in thalassemia, Birth Defects, 23, pp. 35-40, (1988)
[56] Pippard M.J., Callender S.T., The management of iron chelation therapy, British Journal of Hematology, 54, pp. 503-507, (1983)
[57] Polson R.J., Jawed A., Bomford A., Berry H., Willia R., Treatment of rheumatoid arthritis with desferrioxamine: relation between stores of iron before treatment and side effects, British Medical Journal, 291, (1985)
[58] Porter J.B., Jaswon, Huehns E.R., East C.A., Hazell J.W.P., Desferrioxamine toxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage, British Journal of Haematology, 73, pp. 403-409, (1989)
[59] Proper R., Nathan D., Clinical removal of iron, Annual Review of Medicine, 33, pp. 509-519, (1982)
[60] Proudfoot A.T., Simpson D., Dyson E.H., Management of acute iron poisoning, Medical Toxicology, 1, pp. 83-100, (1986)

← 1 2 3 4 5 6 7 8 9 →